This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Intranasal Vaccination: Rationale, Progress and Challenges
Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions
Exploring a Novel Device for Nasal Drug Delivery to the Olfactory System
Publications, Pharmaceutical, Brand Differentiation, Market Insights, Product Solutions, Device Innovations
Intranasal Delivery of Thin-Film Freeze-Dried Vaccine Powders
Publications, Pharmaceutical, Device Innovations, Product Solutions
Exploring the Benefits and Future Possibilities of Nasal Drug Delivery and Drug Repos...
Webinars, Pharmaceutical, Product Solutions, Device Innovations, Brand Differentiation, Market Insights
